Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its second quarter 2026 financial and operating results on August 6, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on August 6, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2026 financial and operating results and to provide a business update.